SLNO FY 2024 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$188M

Net Income

-$176M

EPS (Diluted)

$-4.38

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$100M

Balance Sheet

Total Assets

$331M

Total Liabilities

$86M

Stockholders' Equity

$245M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$188M	-$41M	-353.5%
Net Income	-$176M	-$39M	-351.0%